Brandon Pang, MD
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pang’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$7,325
Medicare paid this office $7,325 for 36 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 15 | $2,724 | $170 |
Who their Medicare patients are
36 Original Medicare patients in 2024. Average age 73 · Women 56% · Health risk score 2.67. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Chronic kidney disease 47% · Atrial fibrillation 44% · Stroke 42% · Coronary heart disease 33% · Heart failure 33% · Cancer 33% · Depression 33%.
The office billed $34,000, Medicare allowed $9,253 and paid $7,325; for 70 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 36 | 70 | 73 | 2.67 | $34,000 | $7,325 |
| 2023 | 12 | 20 | 77 | 2.89 | $12,688 | $2,514 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Drugs they prescribed that Part D paid
$277,021
Pharmacies billed $277,021 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 509) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
208 generic and 301 brand-name prescriptions · $277,021 in drug cost · 18 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 23 | $81,111 | $3,527 |
| Trelegy Ellipta | 68 | $47,138 | $693 |
| Stiolto Respimat | 19 | $8,694 | $458 |
| Incruse Ellipta | 25 | $8,662 | $346 |
| Breo Ellipta | 19 | $8,511 | $448 |
See all 14 drugs
| Dupixent | 23 | $81,111 | $3,527 |
| Trelegy Ellipta | 68 | $47,138 | $693 |
| Stiolto Respimat | 19 | $8,694 | $458 |
| Incruse Ellipta | 25 | $8,662 | $346 |
| Breo Ellipta | 19 | $8,511 | $448 |
| Varenicline | 22 | $2,941 | $134 |
| Ventolin Hfa | 35 | $2,829 | $81 |
| Fluticasone-Salmeterol | 17 | $2,175 | $128 |
| Albuterol Sulfate Hfa | 50 | $1,741 | $35 |
| Fluticasone Propionate | 32 | $485 | $15 |
| Montelukast | 23 | $479 | $21 |
| Azithromycin | 16 | $265 | $17 |
| Omeprazole | 12 | $240 | $20 |
| Spironolactone | 12 | $17 | $1 |
Year by year
| 2024 | 509 | 47 | 0% (0) | 59% | $277,021 |
| 2023 | 537 | 57 | 0% (0) | 58% | $394,496 |
| 2022 | 334 | 53 | 0% (0) | 69% | $218,555 |
| 2021 | 217 | 47 | 0% (0) | None | $39,529 |
| 2020 | 167 | 40 | None | None | $15,274 |
| 2019 | 210 | 45 | 6% (12) | None | $19,902 |
| 2018 | 54 | 17 | None | 20% | $3,864 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Dupixent | 14 | $47,262 | $3,376 |
| Nucala | 12 | $43,095 | $3,591 |
| Dupixent | 11 | $37,799 | $3,436 |
| Trelegy Ellipta | 41 | $28,352 | $692 |
| Spiriva Handihaler | 23 | $17,310 | $753 |
| Breo Ellipta | 23 | $13,013 | $566 |
| Varenicline | 29 | $11,073 | $382 |
| Incruse Ellipta | 26 | $9,703 | $373 |
| Stiolto Respimat | 16 | $7,675 | $480 |
| Fluticasone-Salmeterol | 15 | $1,993 | $133 |
| Ventolin Hfa | 29 | $1,922 | $66 |
| Albuterol Sulfate Hfa | 43 | $1,348 | $31 |
| Fluticasone Propionate | 57 | $742 | $13 |
| Diclofenac | 12 | $536 | $45 |
| Montelukast | 25 | $440 | $18 |
| Azithromycin | 13 | $166 | $13 |
| Prednisone | 20 | $149 | $7 |
2022: 12 drugs
| Nucala | 18 | $58,761 | $3,264 |
| Trelegy Ellipta | 19 | $14,177 | $746 |
| Spiriva Handihaler | 16 | $12,024 | $751 |
| Eliquis | 13 | $11,064 | $851 |
| Breo Ellipta | 27 | $10,983 | $407 |
| Incruse Ellipta | 24 | $9,154 | $381 |
| Varenicline | 12 | $4,281 | $357 |
| Albuterol Sulfate Hfa | 39 | $1,619 | $42 |
| Fluticasone Propionate | 12 | $255 | $21 |
| Montelukast | 11 | $183 | $17 |
| Omeprazole | 15 | $146 | $10 |
| Prednisone | 19 | $94 | $5 |
2021: 3 drugs
| Advair Hfa | 11 | $6,055 | $550 |
| Albuterol Sulfate Hfa | 18 | $1,333 | $74 |
| Atorvastatin | 13 | $299 | $23 |
2020: 1 drug
| Atorvastatin | 23 | $458 | $20 |
2019: 3 drugs
| Xarelto | 12 | $8,983 | $749 |
| Atorvastatin | 19 | $480 | $25 |
| Lisinopril | 19 | $125 | $7 |
Money from drug and device companies
$512 in 2023
| 2023 | 3 | 4 | None | $512 |
| 2022 | 1 | 1 | None | $127 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Tezspire | $245 | 2 payments
|
| United Therapeutics | None | $146 | 1 payment
|
| Amgen | Tezspire | $121 | 1 payment
|
See all 4 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2023-08-08 | Tezspire | $121 |
| Amgen | Meals · 2023-08-08 | Tezspire | $121 |
| United Therapeutics | Meals · 2023-05-23 | None | $146 |
| AstraZeneca Pharmaceuticals LP | Meals · 2023-04-13 | Tezspire | $124 |
See earlier years (2022)
2022: $127
| AstraZeneca Pharmaceuticals LP | Tezspire | $127 | 1 payment
|
Professional record
- NPI
- 1790279040
- Licence
- MA 289492, MI 4301115692
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Internal medicine (207R00000X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2018-06-20
- NPI last updated
- 2025-11-03
- NPI record certified
- 2025-11-03
This is when the NPI record was last certified, not a medical board exam.